{"id":"f09e195bafc3","type":"article","url":"https://hartvaat.nl/2026/10/01/vroege-herkenning-van-fabryziekte-voorkomt-hartfalen-en-neurologische-complicati/","title":"Vroege herkenning van Fabryziekte voorkomt hartfalen en neurologische complicaties","title_en":"Fabry Disease: Cardiac and Neurologic Involvement.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart failure clinics","doi":"10.1016/j.hfc.2026.07.005","source_url":"https://doi.org/10.1016/j.hfc.2026.07.005","authors":["Emanuele Monda","Chiara Cirillo","Marta Rubino","Anna Murredda","Martina Caiazza","Gaetano Diana","Elena Biagini","Giuseppe Limongelli"],"significance":5,"published":"2026-09-19","source_date":"2026-10-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/"],"congress":"","summary_en":"This narrative review outlines the cardiac and neurological manifestations of Fabry disease, including hypertrophic cardiomyopathy, arrhythmias, heart failure, and cerebrovascular events. It emphasizes the importance of early diagnostic suspicion in patients with unexplained cardiac hypertrophy or neuropathy and summarizes current evidence for disease-modifying therapies. Timely recognition and targeted treatment are crucial for cardiologists and internists to prevent progressive organ damage and improve long-term outcomes.","created":"2026-09-12T01:04:28Z","updated":"2026-09-12T01:04:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze overzichtsstudie belicht de hart- en neurologische manifestaties van Fabryziekte, waaronder hypertrofische cardiomyopathie, hartritmestoornissen, hartfalen en cerebrovasculaire gebeurtenissen. De auteurs benadrukken het belang van vroege diagnostiek bij patiënten met een onverklaarde hypertrofie of neuropathie en schetsen de rol van ziekte-modificerende therapieën om progressie te remmen. Voor cardiologen en internisten is tijdige herkenning essentieel om langdurige orgaanschade te voorkomen en de juiste behandeling in te zetten.","abstract_original":"Cardiac and neurologic manifestations are common in Fabry disease (FD) and significantly impact prognosis and quality of life. Cardiac involvement includes hypertrophic cardiomyopathy, arrhythmias, and heart failure, while the main neurologic manifestations are cerebrovascular events and peripheral neuropathy. The progressive nature of these manifestations highlights the importance of early detection and management to prevent long-term damage. This article provides an overview of the key cardiac and neurologic manifestations of FD, offers guidance on when cardiologists and neurologists should suspect FD and start diagnostic evaluation, and summarizes the evidence on the role of disease-modifying therapies in managing cardiovascular and neurologic complications."}